Financial Consulate’s Amneal Pharmaceuticals AMRX Stock Holding History

Financial Consulate’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$222	Buy	+11	New	+$198	﹤0.01%	1665

Other funds holding AMRX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Signature Wealth Management Partners Montvale, New Jersey $234M AUM 23.06% 1-Year Est. Return

Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Diversify Advisory Services Sandy, Utah $6.69B AUM 18.85% 1-Year Est. Return

Diversify Wealth Management Sandy, Utah $6.69B AUM 22.4% 1-Year Est. Return

Campbell Newman Asset Management Milwaukee, Wisconsin $1.33B AUM 26.63% 1-Year Est. Return

Oliver Luxxe Assets Gladstone, New Jersey $638M AUM 30.27% 1-Year Est. Return

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return

Financial Consulate's AMRX Position: Q3 2026 in Review

Financial Consulate opened a new position in Amneal Pharmaceuticals (AMRX) in Q3 2026: 11 shares worth $222. The stake represents ﹤0.01% of the portfolio and ranks #1665 among its holdings.

65 funds tracked by Wall St. Rank hold AMRX as of Q3 2026.

Financial Consulate held 11 shares of Amneal Pharmaceuticals worth $222 as of Q3 2026.
Amneal Pharmaceuticals was a new Financial Consulate position in Q3 2026.
Amneal Pharmaceuticals made up ﹤0.01% of Financial Consulate's portfolio in Q3 2026, its #1665 holding.
65 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2026.

Based on Financial Consulate's 13F filing for Q3 2026, filed 23 Oct 2026.